title: Prior Asymptomatic Parenchymal Hemorrhage Does Not Increase the Risk for Intracranial Hemorrhage after Intravenous Thrombolysis.
abstract: BACKGROUND
  The NINDS trial demonstrated the efficacy of intravenous (IV) recombinant tissue plasminogen activator (rtPA) in improving the neurologic outcome in patients presenting with acute ischemic strokes. Patients who had a prior history of intracranial hemorrhage (ICH) were excluded from this trial, possibly due to a hypothetical increase in the subsequent bleeding risk. Thus, there is little data available, whether against or in favor of, the use of IV rtPA in patients with prior ICH. We aim to aid in determining the safety of IV rtPA in such patients through a retrospective hospital-based single center study.
  
  
  METHODS
  We reviewed the brain imaging of all patients who received IV rtPA at our comprehensive stroke center from January 2006 to April 2014 for evidence of prior ICH at the time of IV rtPA administration. Their outcomes were determined in terms of subsequent development of symptomatic ICH as defined by the NINDS trial.
  
  
  RESULTS
  Brain imaging for 640 patients was reviewed. A total of 27 patients showed evidence of prior ICH at the time of IV thrombolysis, all intra-parenchymal. Only 1 patient (3.7%) developed subsequent symptomatic ICH after the administration of IV rtPA. Of the remaining 613 patients who received IV rtPA, 25 patients (4.1%) developed symptomatic ICH.
  
  
  CONCLUSIONS
  This retrospective study provides Level C evidence that patients with imaging evidence of prior asymptomatic intra-parenchymal hemorrhage presenting with an acute ischemic stroke do not show an increased risk of developing symptomatic ICH after IV thrombolysis.
authors.affiliation: Department of Neurology, State University of NY at Buffalo, Buffalo, N.Y., USA.
authors.forename: Mahmoud AbdelMageed
authors.initials: MA
authors.lastname: AbdelRazek
authors.forename: Ashkan
authors.initials: A
authors.lastname: Mowla
authors.forename: David
authors.initials: D
authors.lastname: Hojnacki
authors.forename: Wendy
authors.initials: W
authors.lastname: Zimmer
authors.forename: Rabab
authors.initials: R
authors.lastname: Elsadek
authors.forename: Nour
authors.initials: N
authors.lastname: Abdelhamid
authors.forename: Lobna
authors.initials: L
authors.lastname: Elsadek
authors.forename: Salman
authors.initials: S
authors.lastname: Farooq
authors.forename: Haris
authors.initials: H
authors.lastname: Kamal
authors.forename: Annemarie
authors.initials: A
authors.lastname: Crumlish
authors.forename: Peyman
authors.initials: P
authors.lastname: Shirani
authors.forename: Marilou
authors.initials: M
authors.lastname: Ching
authors.forename: Robert
authors.initials: R
authors.lastname: Sawyer
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D058070:Asymptomatic Diseases; D001927:Brain Diseases / Q000175:diagnosis; D002545:Brain Ischemia / Q000188:drug therapy*; D002114:Calcinosis / Q000175:diagnosis; D003937:Diagnosis, Differential; D038524:Diffusion Magnetic Resonance Imaging; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D002538:Intracranial Arteriovenous Malformations / Q000175:diagnosis; D020300:Intracranial Hemorrhages / Q000139:chemically induced / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D012306:Risk; D062606:Tertiary Care Centers / Q000706:statistics & numerical data; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator